Novartis reported 10.96B in Operating Expenses for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
AstraZeneca AZN:LN 12.3B 763M
Canopy Growth Corp WEED:CN C$ 290.93M 55.8M
Corcept Therapeutics CORT:US $ 62.16M 2.26M
Novartis NOVN:VX 10.96B 826M
Valeant Pharmaceuticals VRX:CN C$ 1.83B 280M
Zoetis ZTS:US $ 1.46B 130M